Methoxyphenamine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Methoxyphenamine
- DrugBank Accession Number
- DB13624
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Methoxyphenamine (DB13624)
- Weight
- Average: 179.2588
Monoisotopic: 179.131014171 - Chemical Formula
- C11H17NO
- Synonyms
- 2-Methoxymethamphetamine
- Méthoxyphénamine
- Methoxyphenamine
- Methoxyphenaminum
- Metoxifenamina
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Abaloparatide. Acebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Methoxyphenamine. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Methoxyphenamine. Acemetacin The risk or severity of hypertension can be increased when Methoxyphenamine is combined with Acemetacin. Acetazolamide Acetazolamide may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level. Acetophenazine Acetophenazine may decrease the stimulatory activities of Methoxyphenamine. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Methoxyphenamine. Aclidinium The risk or severity of Tachycardia can be increased when Aclidinium is combined with Methoxyphenamine. Acrivastine Methoxyphenamine may decrease the sedative and stimulatory activities of Acrivastine. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Methoxyphenamine. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Methoxyphenamine hydrochloride 52V8BVV7FX 5588-10-3 FGSJNNQVSUVTPW-UHFFFAOYSA-N
Categories
- ATC Codes
- R03CB02 — Methoxyphenamine
- Drug Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Adrenergics for Systemic Use
- Agents producing tachycardia
- Agents that produce hypertension
- Amines
- Amphetamines
- Drugs for Obstructive Airway Diseases
- Ethylamines
- Neurotransmitter Agents
- Non-selective Beta-adrenergic Agonists
- Phenethylamines
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Sympathomimetics
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenethylamines
- Direct Parent
- Amphetamines and derivatives
- Alternative Parents
- Phenylpropanes / Phenoxy compounds / Methoxybenzenes / Anisoles / Aralkylamines / Alkyl aryl ethers / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Amine / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Ether / Hydrocarbon derivative / Methoxybenzene / Organic nitrogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J3Z5SRI26Z
- CAS number
- 93-30-1
- InChI Key
- OEHAYUOVELTAPG-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3
- IUPAC Name
- [1-(2-methoxyphenyl)propan-2-yl](methyl)amine
- SMILES
- CNC(C)CC1=CC=CC=C1OC
References
- General References
- FDA Thailand Product Information: Asmeton-S (methoxyphenamine/noscapine/aminophylline/chlorpheniramine) oral tablets [Link]
- External Links
- Human Metabolome Database
- HMDB0041930
- ChemSpider
- 3974
- 29704
- ChEBI
- 134817
- ChEMBL
- CHEMBL2010507
- Wikipedia
- Methoxyphenamine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.783 mg/mL ALOGPS logP 2.13 ALOGPS logP 2.08 ChemAxon logS -2.4 ALOGPS pKa (Strongest Basic) 10.04 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 21.26 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 54.94 m3·mol-1 ChemAxon Polarizability 20.79 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on June 23, 2017 20:45 / Updated on February 21, 2021 18:54